Literature DB >> 28336728

Unraveling Castleman: progress in a complex process.

Kieron Dunleavy1.   

Abstract

Mesh：

Year:  2017        PMID： 28336728      PMCID： PMC5364344          DOI： 10.1182/blood-2017-02-764654

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  8 in total

1.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease.

Authors:  David C Fajgenbaum; Thomas S Uldrick; Adam Bagg; Dale Frank; David Wu; Gordan Srkalovic; David Simpson; Amy Y Liu; David Menke; Shanmuganathan Chandrakasan; Mary Jo Lechowicz; Raymond S M Wong; Sheila Pierson; Michele Paessler; Jean-François Rossi; Makoto Ide; Jason Ruth; Michael Croglio; Alexander Suarez; Vera Krymskaya; Amy Chadburn; Gisele Colleoni; Sunita Nasta; Raj Jayanthan; Christopher S Nabel; Corey Casper; Angela Dispenzieri; Alexander Fosså; Dermot Kelleher; Razelle Kurzrock; Peter Voorhees; Ahmet Dogan; Kazuyuki Yoshizaki; Frits van Rhee; Eric Oksenhendler; Elaine S Jaffe; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  Blood       Date:  2017-01-13       Impact factor: 22.113

2.  Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot.

Authors:  B CASTLEMAN; V W TOWNE
Journal:  N Engl J Med       Date:  1954-09-02       Impact factor: 91.245

3.  Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.

Authors:  Norihiro Nishimoto; Yuzuru Kanakura; Katsuyuki Aozasa; Takeshi Johkoh; Minoru Nakamura; Shuji Nakano; Nobuaki Nakano; Yasuo Ikeda; Takeshi Sasaki; Kiyoshi Nishioka; Masamichi Hara; Hirokuni Taguchi; Yukihiko Kimura; Yoshiro Kato; Hideki Asaoku; Shunichi Kumagai; Fumio Kodama; Hideko Nakahara; Keisuke Hagihara; Kazuyuki Yoshizaki; Tadamitsu Kishimoto
Journal:  Blood       Date:  2005-07-05       Impact factor: 22.113

4.  Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.

Authors:  Frits van Rhee; Raymond S Wong; Nikhil Munshi; Jean-Francois Rossi; Xiao-Yan Ke; Alexander Fosså; David Simpson; Marcelo Capra; Ting Liu; Ruey Kuen Hsieh; Yeow Tee Goh; Jun Zhu; Seok-Goo Cho; Hanyun Ren; James Cavet; Rajesh Bandekar; Margaret Rothman; Thomas A Puchalski; Manjula Reddy; Helgi van de Velde; Jessica Vermeulen; Corey Casper
Journal:  Lancet Oncol       Date:  2014-07-17       Impact factor: 41.316

Review 5.  Multicentric Castleman disease: Where are we now?

Authors:  Hao-Wei Wang; Stefania Pittaluga; Elaine S Jaffe
Journal:  Semin Diagn Pathol       Date:  2016-05-16       Impact factor: 3.464

6.  Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease.

Authors:  Li Yu; Meifeng Tu; Jorge Cortes; Zijun Y Xu-Monette; Roberto N Miranda; Jun Zhang; Robert Z Orlowski; Sattva Neelapu; Prajwal C Boddu; Mary A Akosile; Thomas S Uldrick; Robert Yarchoan; L Jeffrey Medeiros; Yong Li; David C Fajgenbaum; Ken H Young
Journal:  Blood       Date:  2017-01-18       Impact factor: 22.113

7.  HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.

Authors:  N Dupin; T L Diss; P Kellam; M Tulliez; M Q Du; D Sicard; R A Weiss; P G Isaacson; C Boshoff
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

Review 8.  HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy.

Authors:  David C Fajgenbaum; Frits van Rhee; Christopher S Nabel
Journal:  Blood       Date:  2014-03-12       Impact factor: 22.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.